STOCK TITAN

Seagen Inc - sgen STOCK NEWS

Welcome to our dedicated news page for Seagen (Ticker: sgen), a resource for investors and traders seeking the latest updates and insights on Seagen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seagen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seagen's position in the market.

Rhea-AI Summary
Genmab and Seagen announce additional results from the Phase 3 innovaTV 301 trial, showing that TIVDAK demonstrated a statistically significant reduction in the risk of death in cervical cancer patients compared to chemotherapy. The results were presented at the ESMO Congress 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Seagen Inc. to present detailed results from Phase 3 studies at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
Rhea-AI Summary
Seagen Inc. to report Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
conferences earnings
Rhea-AI Summary
Seagen and Astellas announce positive trial results for PADCEV in combination with KEYTRUDA in bladder cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
-
Rhea-AI Summary
Seagen and Genmab announce positive Phase 3 trial results for TIVDAK in recurrent or metastatic cervical cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Genmab and Seagen announce positive results from Phase 3 innovaTV 301 trial in cervical cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Seagen Inc. announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA in combination with ado-trastuzumab emtansine met its primary endpoint of progression-free survival in patients with HER2-positive breast cancer. Overall survival data are not yet mature. Adverse events were more common in the combination arm of the trial, but no new safety signals emerged.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
-
Rhea-AI Summary
Seagen Inc. reports record net product sales in 2Q23, with a 26% increase over 2Q22. PADCEV and ADCETRIS show strong growth, while TUKYSA performs well. Phase 3 trials for PADCEV, TUKYSA, and TIVDAK expected in 2H23. Acquisition by Pfizer progressing towards close in late 2023 or early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
-
Rhea-AI Summary
Seagen Inc. (Nasdaq: SGEN) to Report Q2 2023 Financial Results, No Conference Call Due to Pfizer Acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
conferences earnings
Seagen Inc

Nasdaq:SGEN

SGEN Rankings

SGEN Stock Data

43.15B
129.83M
0.81%
88.83%
5.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Bothell

About SGEN

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys